307 related articles for article (PubMed ID: 14522926)
1. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Swift L; McHowat J; Sarvazyan N
Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
[TBL] [Abstract][Full Text] [Related]
2. Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2).
McHowat J; Swift LM; Arutunyan A; Sarvazyan N
Cancer Res; 2001 May; 61(10):4024-9. PubMed ID: 11358821
[TBL] [Abstract][Full Text] [Related]
3. Changes in phospholipid content and myocardial calcium-independent phospholipase A2 activity during chronic anthracycline administration.
McHowat J; Swift LM; Crown KN; Sarvazyan NA
J Pharmacol Exp Ther; 2004 Nov; 311(2):736-41. PubMed ID: 15295018
[TBL] [Abstract][Full Text] [Related]
4. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
5. Oxidant-induced inhibition of myocardial calcium-independent phospholipase A2.
McHowat J; Swift LM; Sarvazyan N
Cardiovasc Toxicol; 2001; 1(4):309-16. PubMed ID: 12213969
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-induced phospholipase A2 inhibition.
Swift L; McHowat J; Sarvazyan N
Cardiovasc Toxicol; 2007; 7(2):86-91. PubMed ID: 17652810
[TBL] [Abstract][Full Text] [Related]
7. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
8. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
9. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
12. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
13. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
15. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
16. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes.
Santostasi G; Kutty RK; Krishna G
Toxicol Appl Pharmacol; 1991 Mar; 108(1):140-9. PubMed ID: 2006501
[TBL] [Abstract][Full Text] [Related]
17. Effect of anthracyclines on phospholipase A2 activity and prostaglandin E2 production in rat gastric mucosa.
Grataroli R; Leonardi J; Chautan M; Lafont H; Nalbone G
Biochem Pharmacol; 1993 Aug; 46(3):349-55. PubMed ID: 8347160
[TBL] [Abstract][Full Text] [Related]
18. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
[TBL] [Abstract][Full Text] [Related]
19. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value.
Adamcova M; Lencova-Popelova O; Jirkovsky E; Mazurova Y; Palicka V; Simko F; Gersl V; Sterba M
Int J Cardiol; 2015 Dec; 201():358-67. PubMed ID: 26310978
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
